JP2006515587A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515587A5
JP2006515587A5 JP2004560041A JP2004560041A JP2006515587A5 JP 2006515587 A5 JP2006515587 A5 JP 2006515587A5 JP 2004560041 A JP2004560041 A JP 2004560041A JP 2004560041 A JP2004560041 A JP 2004560041A JP 2006515587 A5 JP2006515587 A5 JP 2006515587A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
composition
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004560041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/005682 external-priority patent/WO2004054563A1/en
Publication of JP2006515587A publication Critical patent/JP2006515587A/ja
Publication of JP2006515587A5 publication Critical patent/JP2006515587A5/ja
Withdrawn legal-status Critical Current

Links

JP2004560041A 2002-12-13 2003-12-03 性的不能を治療する方法 Withdrawn JP2006515587A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
PCT/IB2003/005682 WO2004054563A1 (en) 2002-12-13 2003-12-03 Alpha-2-delta ligand for the treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
JP2006515587A JP2006515587A (ja) 2006-06-01
JP2006515587A5 true JP2006515587A5 (https=) 2006-10-12

Family

ID=32595199

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004560036A Pending JP2006511527A (ja) 2002-12-13 2003-12-03 種々の薬学的用途のためのα2δリガンド
JP2004560041A Withdrawn JP2006515587A (ja) 2002-12-13 2003-12-03 性的不能を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004560036A Pending JP2006511527A (ja) 2002-12-13 2003-12-03 種々の薬学的用途のためのα2δリガンド

Country Status (15)

Country Link
US (8) US7432299B2 (https=)
EP (2) EP1572172A1 (https=)
JP (2) JP2006511527A (https=)
KR (2) KR100703103B1 (https=)
CN (8) CN1726021A (https=)
AU (3) AU2003303037A1 (https=)
BR (2) BR0316753A (https=)
CA (3) CA2451267A1 (https=)
MX (2) MXPA05005665A (https=)
MY (1) MY140525A (https=)
NZ (2) NZ566452A (https=)
PL (2) PL377729A1 (https=)
TW (2) TWI286934B (https=)
WO (3) WO2004054577A1 (https=)
ZA (6) ZA200503862B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
BRPI0414798A (pt) 2003-09-25 2006-11-21 Warner Lambert Co métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
ES2422893T3 (es) * 2004-08-02 2013-09-16 Sami Labs Limited Composiciones y procedimientos para el tratamiento de las afecciones dermatológicas hiperproliferativas
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
DE102007001804A1 (de) * 2007-01-12 2008-07-17 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von GABAB-Rezeptor selektiven Agonisten zur Behandlung entzündlicher Hauterkrankungen
CA2703472A1 (en) * 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
AU2008318311B2 (en) * 2007-11-02 2014-05-15 The Board Of Trustees Of The Leland Stanford Junior University FGF9-related methods for treating anxiety
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CN102432525A (zh) * 2011-10-20 2012-05-02 苏州康润医药有限公司 3-苄基-3-氮杂二环[2,1,0]己烷的实用合成方法
RU2015120478A (ru) 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
US8992951B2 (en) * 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
SG11201505599YA (en) 2013-01-25 2015-08-28 Aldeyra Therapeutics Inc Novel traps in the treatment of macular degeneration
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
ZA201603150B (en) * 2015-05-12 2017-08-30 Cipla Europe Nv Inhaler device
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
KR102741262B1 (ko) 2017-05-26 2024-12-11 노바쎄이 에스에이 전압-게이팅된 칼슘 채널 보조 서브유닛 α2δ 및 이의 용도
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス, インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
CN114599397B (zh) * 2019-10-25 2024-05-28 国立大学法人京都大学 Tau蛋白病的预防或治疗剂
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) 1950-04-04 Nxchj
US2599000A (en) 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4026894A (en) 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
JP3856816B2 (ja) 1992-05-20 2006-12-13 ノースウェスターン ユニヴァーシティ 抗発作治療用のgaba及びl−グルタミン酸類縁体
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP0888325B1 (en) 1996-02-07 2002-05-29 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
WO1997033859A1 (en) 1996-03-14 1997-09-18 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
HU224720B1 (en) 1996-03-14 2006-01-30 Warner Lambert Co Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
IL126999A (en) * 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
ATE361909T1 (de) 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
ATE323067T1 (de) 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
ES2258300T3 (es) 1997-12-16 2006-08-16 Pfizer Products Inc. Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia.
CA2304967C (en) 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
SI1045839T1 (en) 1997-12-16 2004-06-30 Warner-Lambert Company Llc Novel amines as pharmaceutical agents
CN1131855C (zh) 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1-取代-1-氨基甲基-环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
WO1999061424A1 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
WO2000002546A2 (en) * 1998-07-09 2000-01-20 Warner-Lambert Company Use of caba-analogues for treating insomnia
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
US6245801B1 (en) * 1998-09-14 2001-06-12 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids
EP1977745B1 (en) * 1999-04-08 2010-04-07 Warner-Lambert Company LLC Treatment of incontinence
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
ES2317839T3 (es) 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
CN1607201A (zh) * 1999-12-08 2005-04-20 沃尼尔·朗伯公司 立体选择性地合成环状氨基酸的方法
ES2282235T3 (es) * 2000-01-31 2007-10-16 Genaera Corporation Inhibidores de la sintesis de la mucina.
GB0007884D0 (en) * 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
WO2001091736A2 (en) * 2000-05-31 2001-12-06 Warner-Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
IL152770A0 (en) * 2000-06-26 2003-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
MXPA03002090A (es) 2000-09-14 2003-06-19 Gruenenthal Gmbh °-tio-aminoacidos.
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
PE20021046A1 (es) 2000-09-30 2002-12-14 Gruenenthal Chemie Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
BR0115783A (pt) * 2000-11-30 2003-09-16 Pfizer Prod Inc Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase
SK12822003A3 (sk) 2001-04-19 2004-04-06 Warner - Lambert Company Llc Fúzne bicyklické alebo tricyklické aminokyseliny
SK286227B6 (sk) * 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.

Similar Documents

Publication Publication Date Title
JP2006515587A5 (https=)
JP5373405B2 (ja) 選択的アンドロゲン受容体モジュレーター
RU2306309C2 (ru) Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
ES2544532T3 (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
JP2001521020A5 (https=)
RU2008106058A (ru) Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
CN105120866B (zh) 与毒性醛相关的疾病和治疗
JP2021176846A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JPWO2023099592A5 (https=)
JP2009524675A5 (https=)
CA2514384A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
RU2012121577A (ru) Замещенные 3-фенилпропионовые кислоты и их применение
JP2005531516A5 (https=)
JP2006143737A5 (https=)
JP2004501189A5 (https=)
JP2018524304A5 (https=)
JP2003503449A5 (https=)
JP2006504738A5 (https=)
JP2009517411A5 (https=)
JP2004532828A5 (https=)
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
JP2005516035A5 (https=)
JPS61257967A (ja) 2−ピロリドン誘導体
JPH1036365A5 (https=)
JP2007525533A5 (https=)